It is well established that people with severe mental illnesses (SMIs), such as schizophrenia and bipolar disorder, have excess rates of cardiovascular disease (CVD), including myocardial infarctions and strokes.
1 The risk of dying from CVD is 3-fold higher in people with SMI younger than 50 years and 2-fold in those aged 50 to 75 years.
2 There has been an increase in clinical and research efforts addressing this problem, but we lack knowledge regarding the most effective ways to predict and manage cardiovascular risk in people with SMI. We know that the conventional cardiovascular risk factors, including smoking, dyslipidemia (with higher levels of total cholesterol and triglycerides and lower levels of high-density lipoprotein cholesterol [HDL-C]), diabetes mellitus, and obesity and possibly a higher prevalence of hypertension, are more common in people with SMI,
3,4 especially those with well-established mental disorders.
5 There may even be a shared genetic predisposition to comorbidities in patients with SMI. People with SMI are less likely to exercise, have unhealthy diets, and may receive inferior physical health care.
6 Antipsychotic medications may contribute to cardiovascular risk through weight gain and its effect on glucose and lipid metabolism, although mortality studies
2,7,8 that explore the role of antipsychotic medication in premature deaths show inconsistent findings. For example, an 11-year follow up study of people with schizophrenia
7 reported reduced cardiovascular mortality in people treated with olanzapine and clozapine, but methodological issues in the study, particularly unmeasured confounding, have been critiqued in detail.
9